Esomeprazole Strontium Actions

sponsored
Did you have any side effects with this medicine?

Actions of Esomeprazole Strontium in details

infoThe action of the drug on the human body is called Pharmacodynamics in Medical terminology. To produce its effect and to change the pathological process that is happening the body and to reduce the symptom or cure the disease, the medicine has to function in a specific way. The changes it does to the body at cellular level gives the desired result of treating a disease. Drugs act by stimulating or inhibiting a receptor or an enzyme or a protein most of the times. Medications are produced in such a way that the ingredients target the specific site and bring about chemical changes in the body that can stop or reverse the chemical reaction which is causing the disease.
sponsored

Pharmacology: Pharmacodynamics: Mechanism of Action: Esomeprazole Strontium is a proton-pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. The S- and R-isomers are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton-pump, thus, reducing gastric acidity, Esomeprazole Strontium blocks the final step in acid production. This effect is dose-related up to a daily dose of 20-40 mg and leads to inhibition of gastric acid secretion.

Clinical Studies: Healing of Erosive Esophagitis: The healing rates of Esomeprazole Strontium 20 mg and 40 mg, and omeprazole 20 mg (the approved dose for this indication) were evaluated in patients with endoscopically diagnosed erosive esophagitis in 4 multicenter, double-blind, randomized studies. The healing rates were 68.7-70.5% and 89.9-90.6% for Esomeprazole Strontium 20 mg, 71.5-81.7% and 92.2-94.1% for Esomeprazole Strontium 40 mg, and 64.7-69.5% and 84.2-89.8% for omeprazole 20 mg, at weeks 4 and 8, respectively.

Long-Term Maintenance of Healing of Erosive Esophagitis: Two (2) multicenter, randomized, double-blind, placebo-controlled 4-arm trials were conducted in patients with endoscopically confirmed, healed erosive esophagitis to evaluate Esomeprazole Strontium 40 mg (n=174), 20 mg (n=180), 10 mg (n=168) or placebo (n=171) once daily over 6 months of treatment. No additional clinical benefit was seen with Esomeprazole Strontium 40 mg over Esomeprazole Strontium 20 mg. Patients remained in remission significantly longer and the number of recurrences of erosive esophagitis was significantly less in patients treated with Esomeprazole Strontium compared to placebo. In both studies, the proportion of patients on Esomeprazole Strontium who remained in remission and were free of heartburn and other gastroesophageal reflux disease (GERD) symptoms was well-differentiated from placebo. In a 3rd multicenter open-label study of 808 patients treated for 12 months with Esomeprazole Strontium 40 mg, the percentage of patients that maintained healing of erosive esophagitis was 93.7% for 6 months and 89.4% for 1 year.

Symptomatic Gastroesophageal Reflux Disease (GERD): Two (2) multicenter, randomized, double-blind, placebo-controlled studies were conducted in a total of 717 patients comparing 4 weeks of treatment with Esomeprazole Strontium 20 mg or 40 mg once daily versus placebo for resolution of GERD symptoms. Patients had ≥6-month history of heartburn episodes, no erosive esophagitis by endoscopy, and heartburn on at least 4 of the 7 days immediately preceding randomization. The percentage of patients that were symptom-free of heartburn was significantly higher in the Esomeprazole Strontium groups compared to placebo at all follow-up visits (weeks 1, 2 and 4). No additional clinical benefit was seen with Esomeprazole Strontium 40 mg over Esomeprazole Strontium 20 mg. In 3 European symptomatic GERD trials, Esomeprazole Strontium 20 and 40 mg and omeprazole 20 mg were evaluated. No significant treatment-related differences were seen.

Helicobacter pylori Eradication in Patients with Duodenal Ulcer Disease: Two (2) multicenter, randomized, double-blind studies were conducted using a 10-day treatment regimen. The 1st study compared Esomeprazole Strontium 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to Esomeprazole Strontium 40 mg once daily plus clarithromycin 500 mg twice daily. The 2nd study compared Esomeprazole Strontium 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to Esomeprazole Strontium 40 mg once daily. H. pylori eradication rates, defined as at least 2 negative tests and no positive tests from CLOtest, histology and/or culture at 4 weeks post-therapy were significantly higher in the Esomeprazole Strontium plus amoxicillin and clarithromycin group than in the Esomeprazole Strontium plus clarithromycin or Esomeprazole Strontium alone group. The percentage of patients with a healed baseline duodenal ulcer by 4 weeks after the 10-day treatment regimen in the Esomeprazole Strontium plus amoxicillin and clarithromycin group was 75% (n=156) and 57% (n=60) respectively, in the 1st and the 2nd studies (per-protocol analysis).

Pharmacokinetics: After oral administration of Esomeprazole Strontium, peak plasma levels (Cmax) occur at approximately 1.5 hrs (Tmax). The Cmax increases proportionally when the dose is increased and there is a 3-fold increase in the area under the plasma concentration-time curve (AUC) from 20-40 mg. At repeated once-daily dosing with 40 mg, the systemic bioavailability is approximately 90% compared to 64% after a single dose of 40 mg. The mean exposure (AUC) to Esomeprazole Strontium increases from 4.32 micromol·hr/L on day 1 to 11.2 micromol·hr/L on day 5 after 40 mg once daily dosing. The AUC after administration of a single 40 mg dose of Esomeprazole Strontium is decreased by 33-53% after food intake compared to fasting conditions.

Esomeprazole Strontium should be taken at least 1 hr before meals.

The pharmacokinetic profile of Esomeprazole Strontium in patients with symptomatic gastroesophageal reflux disease (GERD) following repeated once daily administration of 20 mg and 40 mg of Esomeprazole Strontium for 5 days is similar to that in healthy volunteers.

Esomeprazole Strontium is 97% bound to plasma proteins. Plasma protein-binding is constant over the concentration range of 2-20 micromol/L. The apparent volume of distribution at steady-state (Vss) in healthy volunteers is approximately 16 L. Esomeprazole Strontium is extensively metabolized in the liver by the cytochrome P450 (CYP450) enzyme system. The metabolites of Esomeprazole Strontium lack antisecretory activity. The major part of Esomeprazole Strontium's metabolism is dependent upon the CYP2C19 isoenzyme which forms the hydroxy and desmethyl metabolites. The remaining amount is dependent on CYP3A4 which forms the sulphone metabolite. CYP2C19 isoenzyme exhibits polymorphism in the metabolism of Esomeprazole Strontium, since some 3% of Caucasians and 15-20% of Asians lack CYP2C19 and are termed poor metabolizers. At steady-state, the ratio of AUC in poor metabolizers to AUC in the rest of the population (extensive metabolizers) is approximately 2. Following administration of equimolar doses, the S- and R- isomers of are metabolized differently by the liver, resulting in higher plasma levels of the S- than the R-isomer. The plasma elimination half-life (t½) of Esomeprazole Strontium is 1-1.5 hrs. Less than 1% of parent drug is excreted in the urine. Approximately 80% of an oral dose of Esomeprazole Strontium is excreted as inactive metabolites in the urine and the remainder is found as inactive metabolites in the feces.

Special Populations: Geriatric: The AUC and Cmax values were slightly higher (25% and 18%, respectively) in the elderly as compared to younger subjects at steady-state. Dosage adjustment based on age is not necessary.

Paediatric: The pharmacokinetics of Esomeprazole Strontium has not been studied in patients <18 years.

Gender: The AUC and Cmax values were slightly higher (13%) in females than in males at steady-state. Dosage adjustment based on gender is not necessary.

Hepatic Insufficiency: In patients with mild and moderate hepatic insufficiency, the AUCs of Esomeprazole Strontium are within the range that could be expected in patients with normal liver function. In patients with severe hepatic insufficiency, the AUCs are 2-3 times higher than in the patients with normal liver function. No dosage adjustment is recommended for patients with mild to moderate hepatic insufficiency (Child-Pugh classes A and B). However, in patients with severe hepatic insufficiency (Child-Pugh class C), a dose of 20 mg once daily should not be exceeded.

Renal Insufficiency: The pharmacokinetics of Esomeprazole Strontium in patients with renal impairment are not expected to be altered relative to healthy volunteers as <1% of Esomeprazole Strontium is excreted unchanged in urine.

How should I take Esomeprazole Strontium?

Take Esomeprazole Strontium strontium exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.

Esomeprazole Strontium strontium comes with a Medication Guide. Read and follow the instructions carefully. Ask your doctor if you have any questions.

It may take several days before Esomeprazole Strontium strontium begins to relieve stomach pain. To help relieve this pain, antacids may be taken with Esomeprazole Strontium strontium, unless your doctor has told you not to use them.

Take Esomeprazole Strontium strontium at least 1 hour before a meal and for the full time of treatment, even if you begin to feel better after a few days.

If you are taking Esomeprazole Strontium strontium to treat an ulcer with an H. pylori infection, take it together with the antibiotics (eg, amoxicillin, clarithromycin).

To use the capsule:

  • Swallow the capsule whole. Do not crush or chew it.
  • If the capsule cannot be swallowed, open it and sprinkle the contents on one tablespoonful of applesauce. Do not heat the applesauce. Swallow the mixture right away. Do not chew or crush the granules. Throw away any remaining mixture.

To use the capsule with a nasogastric (NG) tube:

  • Open the capsule and empty the granules into a 60 mL catheter-tipped syringe and mix it with 50 mL of water.
  • Shake the syringe well for 15 seconds. Hold the syringe with the tip up and check the granules in the tip.
  • Deliver the mixture into the nasogastric tube.
  • Do not inject the granules if they have dissolved or have broken into pieces.
  • Flush the tube with more water to rinse all of the medicine into the stomach.

Dosing

The dose of Esomeprazole Strontium strontium will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of Esomeprazole Strontium strontium. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

  • For oral dosage form (delayed-release capsules):
    • To prevent NSAID-associated gastric ulcer:
      • Adults—24.65 or 49.3 milligrams (mg) once a day for up to 6 months. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.
    • To treat duodenal ulcers with H. pylori infection:
      • Adults—49.3 milligrams (mg) once a day for 10 days. The dose is usually taken together with amoxicillin and clarithromycin. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.
    • To treat erosive esophagitis:
      • Adults—24.65 or 49.3 milligrams (mg) once a day for 4 to 8 weeks. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.
    • To treat gastroesophageal reflux disease (GERD):
      • Adults—24.65 milligrams (mg) once a day for 4 to 8 weeks. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.
    • To treat Zollinger-Ellison syndrome:
      • Adults—49.3 milligrams (mg) two times a day. Your doctor may adjust your dose if needed.
      • Children—Use and dose must be determined by your doctor.

Missed Dose

If you miss a dose of Esomeprazole Strontium strontium, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Esomeprazole Strontium administration

infoAdministration of drug is important to know because the drug absorption and action varies depending on the route and time of administration of the drug. A medicine is prescribed before meals or after meals or along with meals. The specific timing of the drug intake about food is to increase its absorption and thus its efficacy. Few work well when taken in empty stomach and few medications need to be taken 1 or 2 hrs after the meal. A drug can be in the form of a tablet, a capsule which is the oral route of administration and the same can be in IV form which is used in specific cases. Other forms of drug administration can be a suppository in anal route or an inhalation route.
sponsored

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

This medicine is usually given for 4 to 8 weeks only. Your doctor may recommend a second course of treatment if you need additional healing time.

Take each dose with a full glass (8 ounces) of water.

Esomeprazole Strontium should be taken at least one hour before a meal.

Do not crush, chew, break, or open a delayed-release capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time.

You may open the delayed-release capsule and sprinkle the medicine into a spoonful of pudding or applesauce to make swallowing easier. Swallow this mixture right away without chewing. Do not save the mixture for later use. Discard the empty capsule.

Esomeprazole Strontium can be given through a nasogastric (NG) feeding tube. Open the capsule and sprinkle the medicine into a 60-milliliter syringe. Mix in 50 milliliters of water. Place the plunger into the syringe and shake the mixture well. Make sure there are no medicine granules stuck in the tip of the syringe. Attach the syringe to the NG tube and push the plunger down to empty the syringe into the tube. Then flush the tube with more water to wash the contents down.

Take this medication for the full prescribed length of time. Your symptoms may improve before the condition is fully treated.

Call your doctor if your symptoms do not improve or if they get worse while you are taking this medicine.

This medication can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using Esomeprazole Strontium.

Store at room temperature away from moisture and heat.

Esomeprazole Strontium pharmacology

infoPharmacokinetics of a drug can be defined as what body does to the drug after it is taken. The therapeutic result of the medicine depends upon the Pharmacokinetics of the drug. It deals with the time taken for the drug to be absorbed, metabolized, the process and chemical reactions involved in metabolism and about the excretion of the drug. All these factors are essential to deciding on the efficacy of the drug. Based on these pharmacokinetic principles, the ingredients, the Pharmaceutical company decides dose and route of administration. The concentration of the drug at the site of action which is proportional to therapeutic result inside the body depends on various pharmacokinetic reactions that occur in the body.
sponsored

Mechanism Of Action

Esomeprazole Strontium is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, Esomeprazole Strontium blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion.

Pharmacodynamics

Antisecretory Activity

The effect of Esomeprazole Strontium on intragastric pH was determined in patients with symptomatic gastroesophageal reflux disease in two separate studies. In the first study of 36 patients, Esomeprazole Strontium 40 mg and 20 mg capsules were administered over 5 days. The results are shown in the Table 3:

Table 3: Effect on Intragastric pH on Day 5 (N=36)

Figure 3: Maintenance of Healing Rates by Month (Study 178)

Patients remained in remission significantly longer and the number of recurrences of erosive esophagitis was significantly less in patients treated with Esomeprazole Strontium compared to placebo.

In both studies, the proportion of patients on Esomeprazole Strontium who remained in remission and were free of heartburn and other GERD symptoms was well differentiated from placebo.

In a third multicenter open label study of 808 patients treated for 12 months with Esomeprazole Strontium 40 mg, the percentage of patients that maintained healing of erosive esophagitis was 93.7% for six months and 89.4% for one year.

Symptomatic Gastroesophageal Reflux Disease (GERD)

Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in a total of 717 patients comparing four weeks of treatment with Esomeprazole Strontium 20 mg or 40 mg once daily versus placebo for resolution of GERD symptoms. Patients had ≥ 6-month history of heartburn episodes, no erosive esophagitis by endoscopy, and heartburn on at least four of the seven days immediately preceding randomization.

The percentage of patients that were symptom-free of heartburn was significantly higher in the Esomeprazole Strontium groups compared to placebo at all follow-up visits (Weeks 1, 2, and 4).

No additional clinical benefit was seen with Esomeprazole Strontium 40 mg over Esomeprazole Strontium 20 mg.

The percent of patients symptom-free of heartburn by day are shown in the Figures 4 and 5:

Figure 4: Percent of Patients Symptom-Free of Heartburn by Day (Study 225)

Figure 5: Percent of Patients Symptom-Free of Heartburn by Day (Study 226)

In three European symptomatic GERD trials, Esomeprazole Strontium 20 mg and 40 mg and omeprazole 20 mg were evaluated. No significant treatment related differences were seen.

Pediatric Gastroesophageal Reflux Disease (GERD)

1 to 11 Years of Age

In a multicenter, parallel-group study, 109 pediatric patients with a history of endoscopically-proven GERD (1 to 11 years of age; 53 female; 89 Caucasian, 19 Black, 1 Other) were treated with Esomeprazole Strontium once daily for up to 8 weeks to evaluate safety and tolerability. Dosing by patient weight was as follows:

  • weight < 20 kg: once daily treatment with Esomeprazole Strontium 5 mg or 10 mg
  • weight ≥ 20 kg: once daily treatment with Esomeprazole Strontium 10 mg or 20 mg

Patients were endoscopically characterized as to the presence or absence of erosive esophagitis.

Of the 109 patients, 53 had erosive esophagitis at baseline (51 had mild, 1 moderate, and 1 severe esophagitis). Although most of the patients who had a follow up endoscopy at the end of 8 weeks of treatment healed, spontaneous healing cannot be ruled out because these patients had low grade erosive esophagitis prior to treatment, and the trial did not include a concomitant control.

12 to 17 Years of Age

In a multicenter, randomized, double-blind, parallel-group study, 149 adolescent patients (12 to 17 years of age; 89 female; 124 Caucasian, 15 Black, 10 Other) with clinically diagnosed GERD were treated with either Esomeprazole Strontium 20 mg or Esomeprazole Strontium 40 mg once daily for up to 8 weeks to evaluate safety and tolerability. Patients were not endoscopically characterized as to the presence or absence of erosive esophagitis.

Risk Reduction Of NSAID-Associated Gastric Ulcer

Two multicenter, double-blind, placebo-controlled studies were conducted in patients at risk of developing gastric and/or duodenal ulcers associated with continuous use of non-selective and COX-2 selective NSAIDs. A total of 1429 patients were randomized across the 2 studies. Patients ranged in age from 19 to 89 (median age 66.0 years) with 70.7% female, 29.3% male, 82.9% Caucasian, 5.5% Black, weight < 20 kg: once daily treatment with Esomeprazole Strontium 5 mg or 10 mg weight ≥ 20 kg: once daily treatment with Esomeprazole Strontium 10 mg or 20 mg 3.7% Asian, and 8.0% Others. At baseline, the patients in these studies were endoscopically confirmed not to have ulcers but were determined to be at risk for ulcer occurrence due to their age ( ≥ 60 years) and/or history of a documented gastric or duodenal ulcer within the past 5 years. Patients receiving NSAIDs and treated with Esomeprazole Strontium 20 mg or 40 mg once-a-day experienced significant reduction in gastric ulcer occurrences relative to placebo treatment at 26 weeks. See Table 11. No additional benefit was seen with Esomeprazole Strontium 40 mg over Esomeprazole Strontium 20 mg. These studies did not demonstrate significant reduction in the development of NSAID-associated duodenal ulcer due to the low incidence.

Table 11: Cumulative percentage of patients without gastric ulcers at 26 weeks :

Study No. of Patients Treatment Group % of Patients Remaining Gastric Ulcer Free*
1 191 Esomeprazole Strontium 20 mg 95.4
194 Esomeprazole Strontium 40 mg 96.7
184 Placebo 88.2
2 267 Esomeprazole Strontium 20 mg 94.7
271 Esomeprazole Strontium 40 mg 95.3
257 Placebo 83.3
*%= Life Table Estimate. Significant difference from placebo (p < 0.01).

Helicobacter pylori (H. pylori) Eradication In Patients With Duodenal Ulcer Disease

Triple Therapy (Esomeprazole Strontium/amoxicillin/clarithromycin): Two multicenter, randomized, double-blind studies were conducted using a 10 day treatment regimen. The first study (191) compared Esomeprazole Strontium 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to Esomeprazole Strontium 40 mg once daily plus clarithromycin 500 mg twice daily. The second study (193) compared Esomeprazole Strontium 40 mg once daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily to Esomeprazole Strontium 40 mg once daily. H. pylori eradication rates, defined as at least two negative tests and no positive tests from CLOtest, histology and/or culture, at 4 weeks post-therapy were significantly higher in the Esomeprazole Strontium plus amoxicillin and clarithromycin group than in the Esomeprazole Strontium plus clarithromycin or Esomeprazole Strontium alone group. The results are shown in Table 12:

Table 12: H. pylori Eradication Rates at 4 Weeks after 10 Day Treatment Regimen % of Patients Cured [95% Confidence Interval] (Number of Patients )

Study Treatment Group Per-Protocol* Intent-to-Treat†
191 Esomeprazole Strontium plus amoxicillin and clarithromycin 84%‡ 77%‡
[78, 89] [71, 82]
(n=196) (n=233)
Esomeprazole Strontium plus clarithromycin 55% 52%
[48, 62] [45, 59]
(n=187) (n=215)
193 Esomeprazole Strontium plus amoxicillin and clarithromycin 85%§ 78%§
[74, 93] [67, 87]
(n=67) (n=74)
Esomeprazole Strontium 5% 4%
[0, 23] [0, 21]
(n=22) (n=24)
*Patients were included in the analysis if they had H. pylori infection documented at baseline, had at least one endoscopically verified duodenal ulcer ≥ 0.5 cm in diameter at baseline or had a documented history of duodenal ulcer disease within the past 5 years, and were not protocol violators. Patients who dropped out of the study due to an adverse reaction related to the study drug were included in the analysis as not H. pylori eradicated.

†Patients were included in the analysis if they had documented H. pylori infection at baseline, had at least one documented duodenal ulcer at baseline, or had a documented history of duodenal ulcer disease, and took at least one dose of study medication. All dropouts were included as not H. pylori eradicated.

‡p < 0.05 compared to Esomeprazole Strontium plus clarithromycin.

§p < 0.05 compared to Esomeprazole Strontium alone.

The percentage of patients with a healed baseline duodenal ulcer by 4 weeks after the 10 day treatment regimen in the Esomeprazole Strontium plus amoxicillin and clarithromycin group was 75% (n=156) and 57% (n=60) respectively, in the 191 and 193 studies (per-protocol analysis).

Pathological Hypersecretory Conditions Including Zollinger-Ellis On Syndrome

In a multicenter, open-label dose-escalation study of 21 patients (15 males and 6 females, 18 Caucasian and 3 Black, mean age of 55.5 years) with pathological hypersecretory conditions, such as Zollinger- Ellison Syndrome, Esomeprazole Strontium significantly inhibited gastric acid secretion. Initial dose was 40 mg twice daily in 19/21 patients and 80 mg twice daily in 2/21 patients. Total daily doses ranging from 80 mg to 240 mg for 12 months maintained gastric acid output below the target levels of 10 mEq/h in patients without prior gastric acid-reducing surgery and below 5 mEq/hr in patients with prior gastric acidreducing surgery. At the Month 12 final visit, 18/20 (90%) patients had Basal Acid Output (BAO) under satisfactory control (median BAO = 0.17 mmol/hr). Of the 18 patients evaluated with a starting dose of 40 mg twice daily, 13 (72%) had their BAO controlled with the original dosing regimen at the final visit. See Table 13.

Table 13: Adequate Acid Suppression at Final Visit by Dose Regimen

Esomeprazole Strontium dose at the Month 12 visit BAO under adequate control at the Month 12 visit

(N=20)*

40 mg twice daily 13/15
80 mg twice daily 4/4
80 mg three times daily 1/2
*One patient was not evaluated.



References

  1. DailyMed. "ESOMEPRAZOLE STRONTIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. NCIt. "Esomeprazole: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
  3. EPA DSStox. "Esomeprazole: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Esomeprazole Strontium are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Esomeprazole Strontium. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported administration

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 ndrugs.com All Rights Reserved